Description

The HIV-1 pandemic continues to cause millions of new infections and AIDS-related deaths each year, and a majority of these occur in regions of the world with limited access to

The HIV-1 pandemic continues to cause millions of new infections and AIDS-related deaths each year, and a majority of these occur in regions of the world with limited access to antiretroviral therapy. Therefore, an HIV-1 vaccine is still desperately needed. The most successful HIV-1 clinical trial to date used a non-replicating canarypox viral vector and protein boosting, yet its modest efficacy left room for improvement. Efforts to derive novel vectors which can be both safe and immunogenic, have spawned a new era of live, viral vectors.

Reuse Permissions
  • 7.45 MB application/pdf

    Download count: 0

    Details

    Contributors
    Date Created
    • 2016
    Resource Type
  • Text
  • Collections this item is in
    Note
    • Vita
    • Partial requirement for: Ph.D., Arizona State University, 2016
      Note type
      thesis
    • Includes bibliographical references (pages 171-207)
      Note type
      bibliography
    • Field of study: Biological design

    Citation and reuse

    Statement of Responsibility

    by Lydia Rebecca Meador

    Machine-readable links